BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34829367)

  • 1. The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach.
    Ríos-Tamayo R; Puig N; Algarín M; García de Veas Silva JL; Barbosa N; Encinas C; Hernández JÁ; Alonso R; Campos ML; Rodríguez T; Leivas A; Olivares MJ; Sánchez MJ; Paiva B; Lahuerta JJ; Martínez-López J
    Diagnostics (Basel); 2021 Oct; 11(11):. PubMed ID: 34829367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of the relationship of heavy/light chain pairs of immunoglobulin (Hevylite) to the results of gel electrophoresis and nefelometric examination of serum proteins at the time of multiple myeloma diagnosis].
    Ščudla V; Lochman P; Pika T; Zapletalová J; Minařík J; Bačovský J
    Cas Lek Cesk; 2015; 154(6):292-302. PubMed ID: 26750626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
    Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heavy/light chain assay in the monitoring of multiple myeloma.
    Ting HY; Sthaneshwar P; Bee PC; Shanmugam H; Lim M
    Pathology; 2019 Aug; 51(5):507-511. PubMed ID: 31253381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined use of free light chain and heavy/light chain ratios allow diagnosis and monitoring of patients with monoclonal gammopathies: Experience of a single institute, with three exemplar case reports.
    Gagliardi A; Carbone C; Russo A; Cuccurullo R; Lucania A; Cioppa PD; Misso G; Caraglia M; Tommasino C; Mastrullo L
    Oncol Lett; 2016 Oct; 12(4):2363-2370. PubMed ID: 27698801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory and Clinical Settings of Heavy/Light Chain (HLC) Assays in the Management of Monoclonal Gammopathies and Multiple Myeloma.
    Napodano C; Ioannilli L; Basile V; Gulli F; Carnazzo V; Pignalosa S; Di Biase L; Cavaleri E; Racco C; Equitani F; Marino M; Basile U
    J Pers Med; 2023 Apr; 13(5):. PubMed ID: 37240913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits of new immunoglobulin-derived biomarkers for the diagnosis and follow-up of patients with dysglobulinemia.
    Ermak N; Nguyen-Khoa T; Alyanakian MA
    Ann Biol Clin (Paris); 2016 Oct; 74(5):597-605. PubMed ID: 27707674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heavy/light chain assay as a biomarker for diagnosis and follow-up of multiple myeloma.
    Chae H; Han E; Yoo J; Lee J; Lee JJ; Cha K; Kim M; Kim Y; Lee SE; Min CK
    Clin Chim Acta; 2018 Apr; 479():7-13. PubMed ID: 29324245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoglobulin heavy chain/light chain pairs (HLC, Hevylite™) assays for diagnosing and monitoring monoclonal gammopathies.
    Kraj M
    Adv Clin Exp Med; 2014; 23(1):127-33. PubMed ID: 24596015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical performance and diagnostic potential of immunoassays determining intact immunoglobulin kappa/lambda ratios in monoclonal gammopathies.
    Eckold J; Poenisch W; Drogies T; Kratzsch J; Teupser D; Thiery J; Bruegel M
    Clin Lab; 2014; 60(9):1491-500. PubMed ID: 25291945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients.
    Batinić J; Perić Z; Šegulja D; Last J; Prijić S; Dubravčić K; Volarić L; Sertić D; Radman I; Bašić-Kinda S; Matišić D; Batinić D; Labar B; Nemet D
    Croat Med J; 2015 Jun; 56(3):263-71. PubMed ID: 26088851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of the assessment of heavy/light chain pairs of immunoglobulin in monoclonal gammopathies].
    Ščudla V; Pika T; Minařík J
    Vnitr Lek; 2015 Jan; 61(1):60-1, 63-71. PubMed ID: 25693618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum and Urine Protein Electrophoresis and Serum-Free Light Chain Assays in the Diagnosis and Monitoring of Monoclonal Gammopathies.
    Singh G
    J Appl Lab Med; 2020 Nov; 5(6):1358-1371. PubMed ID: 33150391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.
    Greil C; Ihorst G; Gaiser F; Salzer U; Bisse E; Kastritis E; Ludwig H; Wäsch R; Engelhardt M
    Eur J Haematol; 2017 Nov; 99(5):449-458. PubMed ID: 28886228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analytical validation of the Hevylite assays for M-protein quantification.
    Jacobs JFM; Haagen IA; Lodder A; van der Kroft C; de Kat Angelino CM; Croockewit S; Nieuwenhuys E; Gelderman KA
    Clin Chem Lab Med; 2018 Jun; 56(7):1169-1175. PubMed ID: 29397379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.
    Boyle EM; Fouquet G; Guidez S; Bonnet S; Demarquette H; Dulery R; Herbaux C; Noel MP; Manier S; Schraen S; Onraed B; Faucompré JL; Hennache B; Petillon MO; Mathiot C; Avet-Loiseau H; Facon T; Harding SJ; Moreau P; Leleu X
    Cancer; 2014 Dec; 120(24):3952-7. PubMed ID: 25116271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.
    Ludwig H; Milosavljevic D; Zojer N; Faint JM; Bradwell AR; Hübl W; Harding SJ
    Leukemia; 2013 Jan; 27(1):213-9. PubMed ID: 22955329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunofluorescence staining for immunoglobulin heavy chain/light chain on kidney biopsies is a valuable ancillary technique for the diagnosis of monoclonal gammopathy-associated kidney diseases.
    Nasr SH; Fidler ME; Said SM; Koepplin JW; Altamirano-Alonso JM; Leung N
    Kidney Int; 2021 Jul; 100(1):155-170. PubMed ID: 33774084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple Myeloma With Deep Responses.
    Miyazaki K; Suzuki K
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):293-296. PubMed ID: 29472112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy].
    Guenet L; Decaux O; Lechartier H; Ropert M; Grosbois B
    Rev Med Interne; 2007 Oct; 28(10):689-97. PubMed ID: 17566612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.